Global HIV Diagnostics Market to Reach USD 6,128.95 Million by 2031 | CAGR of 6.6%
Category : Pharmaceuticals | Published Date : Nov 2024 | Type : Press Release
HIV Diagnostics Market Scope & Overview:
In the newly published report, Consegic Business Intelligence states that the HIV Diagnostics Market was valued at USD 3,701.57 million in 2023 and is projected to grow at a CAGR of 6.6%, reaching USD 6,128.95 million by 2031. HIV diagnostics encompass a range of tests and instruments aimed at detecting the virus or antibodies in the body. These tests include rapid diagnostic tests (RDTs), nucleic acid tests (NATs), and enzyme-linked immunosorbent assays (ELISA), which are vital for early detection and treatment of HIV, improving health outcomes globally.
The report comprises the HIV Diagnostics Market Share, Size & Industry Analysis, based on Type (Instruments, Software & Services), End-User (Hospitals & Clinics, Diagnostic Laboratories, Homecare Settings), and Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), and Forecast, 2024-2031.
The report contains detailed information on HIV Diagnostics Market Trends, Opportunities, Value, Growth Rate, Segmentation, Geographical Coverage, Company Profiles, In-depth Expert Analysis, Revenue Forecast, Competitive Landscape, Growth Factors, Restraints or Challenges, Environment & Regulatory Landscape, PESTLE Analysis, PORTER Analysis, Key Technology Landscape, Value Chain Analysis, and Cost Analysis.
The growing prevalence of HIV globally, coupled with innovations in diagnostic kits for early detection, is driving market growth. Additionally, advancements in genome-based HIV detection techniques present lucrative opportunities for the market's expansion.
Segmental Analysis :
Based on type, the market is segmented into Instruments and Software & Services.
- The instruments segment held the largest market share in 2023, driven by the widespread adoption of diagnostic tools like RDTs, NATs, and ELISA tests. These instruments provide accurate and timely results, facilitating early diagnosis and treatment.
- The software & services segment is expected to grow at the fastest CAGR over the forecast period, supported by advancements in data management tools and the increasing adoption of cloud-based platforms for patient monitoring and diagnostic accuracy.
Based on end-user, the market is segmented into Hospitals & Clinics, Diagnostic Laboratories, and Homecare Settings.
- The hospitals & clinics segment accounted for the largest market share of 43.77% in 2023, driven by the availability of advanced diagnostic tools and comprehensive healthcare services under one roof.
- The homecare settings segment is projected to grow at the fastest rate, driven by the increasing adoption of self-testing kits and patient-centered care approaches, particularly in remote areas.
Based on regions, the market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
- North America: Held the largest market share of 38.02% in 2023, valued at USD 1,407.34 million, supported by advanced diagnostic technologies and widespread public awareness campaigns.
- Asia-Pacific: Expected to grow at the highest CAGR of 6.9%, driven by improved access to diagnostic facilities, increased healthcare investments, and technological advancements in HIV testing.
| Report Attributes | Report Details |
| Study Timeline | 2018-2031 |
| Market Size in 2031 | USD 6,128.95 Million |
| CAGR (2024-2031) | 6.6% |
| Type | Instruments, Software & Services |
| End-User | Hospitals & Clinics, Diagnostic Laboratories, Homecare Settings |
| By Region | North America(U.S., Canada, Mexico) Europe(U.K., Germany, France, Spain, Italy, Russia, Benelux, Rest of Europe) APAC(China, South Korea, Japan, India, Australia, ASEAN, Rest of Asia-Pacific) Middle East & Africa(GCC, Turkey, South Africa, Rest of MEA) LATAM(Brazil, Argentina, Chile, Rest of LATAM) |
Top Key Players & Competitive Landscape :
The competitive landscape encompasses major innovators, aftermarket service providers, industry giants, and niche players, all of which are thoroughly examined by Consegic Business Intelligence in terms of their strengths, weaknesses, and value-addition potential. This report includes detailed profiles of key players, market share analysis, mergers and acquisitions, resulting market fragmentation, and emerging partnership trends and dynamics.
List of prominent players in the HIV Diagnostics Industry:
- Abbott (United States)
- Meril Life Sciences Pvt. Ltd. (India)
- Wantai BioPharm (China)
- Bio-Rad Laboratories, Inc. (United States)
- Hologic, Inc. (United States)
- Siemens Healthcare Private Limited (India)
- Beckman Coulter, Inc. (United States)
- OraSure Technologies Inc. (United States)
- QIAGEN (Germany)
Recent Industry Developments :
- 2024: The Ministry of Health launched a new self-testing kit for HIV in India, enabling individuals to test themselves in the privacy of their homes, improving accessibility to HIV diagnostics.
- 2023: Thermo Fisher Scientific introduced an enhanced version of its Applied Biosystems HIV-1 Genotyping Kit, improving sensitivity and accuracy in detecting and characterizing HIV viral load.
- 2023: Nagaland inaugurated its first HIV-1 Viral Load Laboratory at Naga Hospital Authority Kohima, enhancing regional diagnostic capabilities.
